Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Novo Nordisk A/S
  6. News
  7. Summary
    NOVO B   DK0060534915

NOVO NORDISK A/S

(NOVO B)
  Report
Real-time Estimate Quote. Real-time Estimate Cboe Europe - 01/19 06:48:14 am
629.7 DKK   -0.62%
01/14Novo Nordisk Settles Securities Case in Denmark
MT
01/14Novo Nordisk announces settlement of securities lawsuit in Denmark
AQ
01/10Novo Nordisk A/S – Share repurchase programme
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Novo Nordisk A/S – Share repurchase programme

11/29/2021 | 10:20am EST

Bagsværd, Denmark, 29 November 2021 – On 5 November 2021, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 3 February 2021.

Under the programme initiated 5 November 2021, Novo Nordisk will repurchase B shares for an amount up to DKK 3.7 billion in the period from 11 November 2021 to 1 February 2022.

Since the announcement 22 November 2021, the following transactions have been made:

 Number of
B shares
Average
purchase price
Transaction
value, DKK
Accumulated, last announcement703,000 523,952,190
22 November 2021100,000750.1375,013,122
23 November 2021105,000722.2775,837,883
24 November 2021105,000724.7176,094,782
25 November 202195,000722.8268,668,365
26 November 202195,000711.4067,582,806
Accumulated under the programme1,203,000 887,149,148

The details for each transaction made under the share repurchase programme are published on novonordisk.com.

With the transactions stated above, Novo Nordisk owns a total of 29,392,732 B shares of DKK 0.20 as treasury shares, corresponding to 1.3% of the share capital. The total amount of A and B shares in the company is 2,310,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 20 billion during a 12-month period beginning 3 February 2021. As of 26 November 2021, Novo Nordisk has since 3 February 2021 repurchased a total of 30,639,181 B shares at an average share price of DKK 560.81 per B share equal to a transaction value of DKK 17,182,675,592.

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 47,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, and YouTube.

Further information

Media:  
Mette Kruse Danielsen+45 3079 3883mkd@novonordisk.com
Michael Bachner (US)+1 609 664 7308mzyb@novonordisk.com
   
Investors:  
Daniel Muusmann Bohsen+45 3075 2175dabo@novonordisk.com
Ann Søndermølle Rendbæk+45 3075 2253arnd@novonordisk.com
David Heiberg Landsted+45 3077 6915dhel@novonordisk.com
Mark Joseph Root (US)+1 848 213 3219mjhr@novonordisk.com

Company announcement No 77 / 2021

Attachment

  • CA_211129_SafeHarbour

© OMX, source GlobeNewswire - EU Press Releases

All news about NOVO NORDISK A/S
01/14Novo Nordisk Settles Securities Case in Denmark
MT
01/14Novo Nordisk announces settlement of securities lawsuit in Denmark
AQ
01/10Novo Nordisk A/S – Share repurchase programme
AQ
01/062Seventy Bio Working With Novo Nordisk to Develop Potential Gene-Editing Treatment for ..
MT
01/062seventy bio, Inc. Announces Expanded Collaboration Agreement with Novo Nordisk to Cont..
CI
01/06NOVO NORDISK : Deutsche Bank remains Neutral
MD
01/06NOVO NORDISK : Receives a Sell rating from Jefferies
MD
01/05Humanwell Healthcare to Sell Entire RiteDose Stake For $174 Million; Shares Jump 3%
MT
01/04NOVO NORDISK : Gets a Neutral rating from JP Morgan
MD
01/04NOVO NORDISK : Bernstein reiterates its Buy rating
MD
More news
Analyst Recommendations on NOVO NORDISK A/S
More recommendations
Financials
Sales 2021 140 B 21 296 M 21 296 M
Net income 2021 47 537 M 7 244 M 7 244 M
Net Debt 2021 1 027 M 157 M 157 M
P/E ratio 2021 30,6x
Yield 2021 1,60%
Capitalization 1 443 B 220 B 220 B
EV / Sales 2021 10,3x
EV / Sales 2022 9,40x
Nbr of Employees 46 982
Free-Float 69,8%
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 26
Last Close Price 633,60 DKK
Average target price 673,26 DKK
Spread / Average Target 6,26%
EPS Revisions
Managers and Directors
Lars Fruergaard J°rgensen President & Chief Executive Officer
Karsten Munk Knudsen Chief Financial Officer & Executive Vice President
Helge Lund Chairman
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Henrik Ehlers Wulff Senior Vice President-Diabetes API
Sector and Competitors
1st jan.Capi. (M$)
NOVO NORDISK A/S-13.80%219 759
JOHNSON & JOHNSON-2.32%439 907
ROCHE HOLDING AG-3.75%322 066
PFIZER, INC.-8.37%303 712
ABBVIE INC.1.02%241 811
ELI LILLY AND COMPANY-10.55%223 992